Appendectomy successfully averted in child considered at high surgical risk

Publication
Article
Contemporary PEDS JournalVol 37 No 7
Volume 37
Issue 7

A case report examines whether a high-risk child with appendicitis will need surgery.

A recent case report describes how appendicitis in a 9-year-old child with sickle cell disease was handled effectively with nonsurgical treatment.

The child, who has sickle beta zero thalassemia and moderate persistent asthma, visited an emergency department because of lower back, chest, and abdominal pain that had not responded to ibuprofen. Doctors diagnosed vasoocclusive crisis, and the child was given intravenous fluids and analgesia. Abdominal ultrasound did not visualize the appendix, and results of abdominal computerized tomography were consistent with acute appendicitis without perforation.

Considered a high surgical risk, the child was given medical therapy, including ciprofloxacin and metronidazole, and after a day of not eating was transitioned to a full liquid diet. By the fifth day of hospitalization his respiration had improved significantly, and he was discharged on day 6. A year later, his abdominal pain had not returned (Sahib S, et al. J Pediatr Hematol Oncol. March 3, 2020. Online ahead of print.).

Thoughts from Dr. Farber

Although rarely discussed in pediatric literature, using medical therapy with early introduction of antibiotics for acute appendicitis is not a new concept. Given how easily and relatively risk free appendectomy is to perform (especially laparoscopically), surgery is still the standard of care. However, keep an open mind about medical treatment if a surgeon believes that operating might be the greater risk.

Recent Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Juanita Mora, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.